top of page

DRUG DISCOVERY PIPELINE

Since its inception in 2014, FNDR has generated a portfolio of therapeutics in tuberculosis, nontuberculosis mycobacteria, malaria, dengue, leishmania, bacterial infections, COVID-19 and RSV, spanning over early-stage discovery to late-stage clinical trials. Click here for FNDR's areas of research focus, our publications and information about our research programs.

Hit to Lead
Lead Optimization
IND Enabling Studies
Repurposed Drugs
Phase 1
Phase 2
Phase 3

TUBERCULOSIS

NONTUBERCULOUS MYCOBACTERIA

BACTERIAL INFECTIONS

FUNGAL INFECTIONS

MALARIA

LEISHMANIA

COVID-19

RESPIRATORY SYNCYTIAL VIRUS

DENGUE

CONTRACT SERVICES

FNDR performs various preclinical in vitro and animal studies for BSL-2 and BSL-3 bacterial, fungal and viral pathogens under a fee-for-service mode to test therapeutics, vaccines, and other items. Click here for more information.

Therapeutics Testing 
Vaccines Testing

Virucidal Assays

In vitro Models
Animal Models

ACHIEVEMENTS

1

Drug in Clinical Development

30+

Ongoing Innovation Projects on Infectious Disease Drug Discovery and Platform Technologies.

4

Repurposed drugs under development

100+

Contract Research Projects Completed

13

New Drugs in Preclinical Development

50+

Research and Development Partners

LATEST NEWS

Positive results from Phase 2A clinical trial of TBA-7371, a new drug candidate for tuberculosis

29 November 2023

Foundation for Neglected Disease Research (FNDR) is proud to announce that its partners, Bill & Melinda Gates Medical Research Institute and TB Alliance, have successfully completed the Phase 2A Early Bactericidal Activity clinical trial of TBA-7371, a novel DprE1 inhibitor for the treatment of tuberculosis. The results were presented at the 2023 Union World Conference on Lung Health in Paris. TBA-7371 was well tolerated and showed significant dose-dependent bactericidal activity with 14 days of treatment in patients with drug-susceptible pulmonary tuberculosis. TBA-7371 could have significant potential in the treatment of TB.

bottom of page